Information Provided By: 
Fly News Breaks for July 1, 2019
ATRA
Jul 1, 2019 | 09:49 EDT
Atara Biotherapeutics reported that 18 patients received ATA-188 at three different dose levels without dose limiting toxicity or adverse events leading to discontinuation, which bodes well for Phase 2, Canaccord Genuity analyst John Newman tells investors in a research note. The analyst maintains a Buy rating on the shares with a $70 price target as he awaits efficacy for ATA-188 in the second half of 2019. He views the safety data in multiple sclerosis as "clean."
News For ATRA From the Last 2 Days
There are no results for your query ATRA
